Blood test for melanoma with BRAF V600E mutation
Part of Cancer, Skin clinical trials.
This trial studies a very sensitive blood test to detect melanoma-related genetic changes in people with BRAF V600E. It may help track the disease more closely and guide care in advanced or high-risk situations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have confirmed skin (cutaneous) melanoma.
- Your melanoma has the BRAF V600E mutation.
- You are able and eligible to receive either BRAF/MEK targeted pills (BRAFi/MEKi) or immunotherapy that helps your immune system (checkpoint blockade).
- Your life expectancy is at least 8 weeks.
- You can and are willing to sign informed consent and have blood drawn as required.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a simple blood test (liquid biopsy) to track how well melanoma responds to immunotherapy. It might help doctors decide if treatment is working or needs to be changed.
This study looks at serial (repeated) tumour biopsies and blood samples in people with advanced melanoma. The goal is to understand biomarkers and disease changes over time, which may help improve future treatment decisions.
This trial studies whether certain gene patterns and a blood test can help predict how melanoma might behave. It is for people with a thicker melanoma (greater than 2 mm) that has not spread to lymph nodes or other parts of the body, and who are planning to have a sentinel lymph node biopsy.
This study follows people with BRAF V600E–positive metastatic colorectal (colon) cancer to better understand how the cancer’s biology changes over time. It may help researchers learn which features to watch and how this cancer behaves after initial treatment.
This trial is researching colorectal cancer that has a specific genetic change called BRAF V600E. It uses advanced testing (multi-omics) to learn more about the cancer and find better ways to treat it.
This trial tests a personalized approach where doctors monitor tumor DNA in your blood to decide when to pause targeted therapy (encorafenib and binimetinib) for advanced melanoma with a BRAF mutation. The goal is to see if treatment breaks can be safe and effective.
Hear when a new Liquid Biopsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.